FDA Evaluates Ovarian Cancer ADC Maintenance Benefit-Risk Standards as Kenya Begins 42-Day Ebola-Free Countdown
The U.S. FDA Oncology Center of Excellence convened a public workshop on progression-free and overall survival endpoints for ovarian cancer maintenance therapies including antibody-drug conjugates, while Kenya launched its 42-day countdown to Ebola-free certification and WHO recommended two Bundibugyo vaccine candidates.
By 全球伯乐 News
Medical R&D & Global Health Security Desk
On this page
Between November 11 and November 12, 2026, oncology regulators and infectious-disease authorities marked critical milestones in clinical trial methodology and outbreak containment: on November 12, the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence convened Day 1 of its public workshop titled 'Maintenance Treatment for Ovarian Cancer Workshop: Weighing Benefit and Toxicity in an Evolving Landscape', examining regulatory standards for antibody-drug conjugates (ADCs) and other emerging maintenance regimens1. On the same day, Kenya officially began Day 1 of a 42-day countdown toward being declared Ebola-free after discharging its final Bundibugyo virus survivor and last 11 quarantined contacts2, while WHO Director-General Dr. Tedros Adhanom Ghebreyesus briefed Member States in Geneva on vaccine trials and security challenges in the Democratic Republic of the Congo (DRC) outbreak3.

AI-generated illustration: Editorial still-life concept representing oncology maintenance benefit-risk trial evaluation and infectious disease surveillance countdowns, not a clinical photograph.
FDA Oncology Center of Excellence Reassesses PFS, OS Detriment Monitoring, and Biomarkers in Ovarian Cancer Maintenance
According to the FDA Oncology Center of Excellence workshop notice (with Session 1 held on November 12 and Session 2 scheduled for November 19, 2026), novel agents—particularly antibody-drug conjugates—are increasingly being tested as prolonged maintenance treatments for ovarian cancer despite carrying substantial cumulative toxicities1. Workshop panels brought together FDA reviewers, clinicians, drug developers, and patient representatives to establish what magnitude of progression-free survival (PFS) improvement is clinically meaningful in the maintenance setting1.
Crucially, the FDA agenda emphasized the need to incorporate overall survival (OS) into maintenance trial design to monitor for potential OS detriment arising from long-term treatment toxicity1. Participants also evaluated strategies for dose optimization and predictive biomarker integration so regulatory approvals and drug labels accurately target patient subpopulations whose benefit outweighs chronic adverse effects1.
Kenya Launches 42-Day Countdown Toward December 23 Ebola-Free Declaration as WHO Advances Bundibugyo Vaccine Candidates
In East Africa, rapid contact tracing contained an imported filovirus outbreak before community transmission could take hold. As announced by Kenyan Health Cabinet Secretary Aden Duale and WHO Africa Programme Management Director Dr. Abdourahmane Diallo, Kenya confirmed its index case of Bundibugyo virus disease on October 6, 2026, in a traveler returning from the DRC via Uganda, and swiftly quarantined all 135 contacts at home and abroad2. All eight secondary cases (four family members and four frontline healthcare workers) were already in quarantine when symptoms appeared; no new cases have been recorded since October 19, and with seven total recoveries (and two deaths), the November 11 discharge of the final patient initiated a 42-day surveillance countdown on November 12 that will declare Kenya Ebola-free on December 23, 2026 if no further cases emerge2.
Meanwhile, WHO Director-General Dr. Tedros reported to Member States that the active DRC outbreak has now reached nearly 11,000 confirmed cases, more than 5,300 deaths, and nearly 3,000 recoveries across eight provinces3. Warning that armed violence—including an attack last week in Cantine-Aloya that killed 66 civilians including three health workers, burned three clinics, and left more than 1,000 contacts lost to follow-up—remains the gravest barrier to containment, Dr. Tedros announced that alongside an Ervebo vaccine trial launched in October, WHO expert groups have recommended adding two vaccine candidates specifically targeting the Bundibugyo virus while the DRC government updates its national response plan through January 202723.
Source notes
-
2026-11-12 · FDA Public Virtual Only Workshop: Maintenance Treatment for Ovarian Cancer Workshop: Weighing Benefit and Toxicity in an Evolving Landscape - 11/12/2026 · U.S. Food and Drug Administration (FDA). ↩ ↩2 ↩3 ↩4 ↩5
-
2026-11-11 · Kenya's last Ebola patient goes home as 42-day countdown begins · WHO Regional Office for Africa. ↩ ↩2 ↩3 ↩4
-
2026-11-11 · WHO Director-General's opening remarks at the Member State briefing on Ebola outbreak in the Democratic Republic of the Congo – 11 November 2026 · World Health Organization (WHO). ↩ ↩2 ↩3


